Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs

被引:168
作者
Perry, EK
Kilford, L
Lees, AJ
Burn, DJ
Perry, RH
机构
[1] Newcastle Gen Hosp, Wolfson Res Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[2] Newcastle Gen Hosp, Dept Neuropathol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[3] UCL, Inst Neurol, Sara Koe PSP Res Ctr, London, England
[4] Royal Free & UCL Med Sch, Reta Lila Weston Inst Neurol Studies, London, England
关键词
D O I
10.1002/ana.10639
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The hypothesis that blockade of muscarinic receptors is associated with increased Alzheimer-type pathology was investigated in Parkinson's disease. Amyloid plaque densities were more than 2.5-fold higher in cases treated with antimuscarinic medication in the long term compared with untreated or short-term treated cases (p = 0.005 and 0.00005, respectively). Neurofibrillary tangle densities were also highest in chronic compared with untreated or acute-treated groups (p = 0.02 and 0.05, respectively). The findings, if replicated, have potential implications for the use of anticholinergic medication in elderly Parkinson's disease patients.
引用
收藏
页码:235 / 238
页数:4
相关论文
共 21 条
  • [1] Ageing of the brain
    Anderton, BH
    [J]. MECHANISMS OF AGEING AND DEVELOPMENT, 2002, 123 (07) : 811 - 817
  • [2] Reduction of cortical amyloid β levels in guinea pig brain after systemic administration of physostigmine
    Beach, TG
    Kuo, YM
    Schwab, C
    Walker, DG
    Roher, AE
    [J]. NEUROSCIENCE LETTERS, 2001, 310 (01) : 21 - 24
  • [3] Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists
    Beach, TG
    Walker, DG
    Potter, PE
    Sue, LI
    Fisher, A
    [J]. BRAIN RESEARCH, 2001, 905 (1-2) : 220 - 223
  • [4] THE MUSCARINIC M1 AGONIST XANOMELINE INCREASES SOLUBLE AMYLOID PRECURSOR PROTEIN RELEASE FROM CHINESE-HAMSTER OVARY-M1 CELLS
    ECKOLS, K
    BYMASTER, FP
    MITCH, CH
    SHANNON, HE
    WARD, JS
    DELAPP, NW
    [J]. LIFE SCIENCES, 1995, 57 (12) : 1183 - 1190
  • [5] Farlow MR, 2002, INT J CLIN PRACT, P37
  • [6] Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3β inhibition and in neurons
    Forlenza, OV
    Spink, JM
    Dayanandan, R
    Anderton, BH
    Olesen, OF
    Lovestone, S
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2000, 107 (10) : 1201 - 1212
  • [7] Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment
    Genis, I
    Fisher, A
    Michaelson, DM
    [J]. JOURNAL OF NEUROCHEMISTRY, 1999, 72 (01) : 206 - 213
  • [8] NGF PROMOTES AMYLOID PRECURSOR PROTEIN SECRETION VIA MUSCARINIC RECEPTOR ACTIVATION
    HARING, R
    GURWITZ, D
    BARG, J
    PINKASKRAMARSKI, R
    HELDMAN, E
    PITTEL, Z
    DANENBERG, HD
    WENGIER, A
    MESHULAM, H
    MARCIANO, D
    KARTON, Y
    FISHER, A
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 213 (01) : 15 - 23
  • [9] Hock C, 2000, ANN NY ACAD SCI, V920, P285
  • [10] A CLINICOPATHOLOGICAL STUDY OF 100 CASES OF PARKINSONS-DISEASE
    HUGHES, AJ
    DANIEL, SE
    BLANKSON, S
    LEES, AJ
    [J]. ARCHIVES OF NEUROLOGY, 1993, 50 (02) : 140 - 148